Summary of Use during Lactation

No information is available on the clinical use of naxitamab during breastfeeding. Because naxitamab is a large protein molecule with a molecular weight of about 144,000 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. The manufacturer recommends that breastfeeding be discontinued during naxitamab therapy and for 2 months after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Name

Naxitamab

CAS Registry Number

1879925-92-4

Drug Class

Breast Feeding

Lactation

Milk, Human

Antineoplastic Agents

Antibodies, Monoclonal